Skip to main content

Incyte Expands Roche and AstraZeneca Partnerships


PALO ALTO, Calif.--Incyte Pharmaceuticals announced the expansion and extension of its agreements with Hoffmann-La Roche and AstraZeneca, continuing deals that were originally signed in 1996. AstraZeneca's expanded arrangement will include access to Incyte's LifeSeq Gold database of human gene sequence and expression data, its ZooSeq animal model database, and additional genomic databases and services. The Roche agreement grants access to LifeSeq Gold, ZooSeq, and continued access to the LifeSeq Atlas mapping database in exchange for annual access fees. In addition, Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information. Financial terms for both agreements were not disclosed. The combination of the ZooSeq and the LifeSeq Gold databases enable scientists to make comparisons between human and animal pathways, Incyte said.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.